New Thinking Needed On Reimbursement Of Cell And Gene Therapies

One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Health Systems Must Plan For Systematic Uptake Of Advanced Therapies • Source: Shutterstock

At least 12 new advanced therapy medicinal products (ATMPs) are expected to get market approval in either the US or the EU over the next 18 months, and there are hundreds more in the pipeline, but a lot needs to be done to prepare healthcare systems for the routine, systematic uptake of these therapies.

There is no doubt that healthcare providers recognize the “remarkable" value of these therapies and "we have had some pretty...

More from United Kingdom

More from Europe